Bifidobacterium Longumbl‐19 Inhibits Oxidative Stress and Inflammatory Damage in the Liver of Mice with NAFLD by Regulating the Production of Butyrate in the Intestine

Nonalcoholic fatty liver disease (NAFLD) is a common chronic liver disease, but there is currently no effective treatment method. Probiotics have been used as an adjunct therapy for NAFLD, but the mechanism is not clear. This study used Bifidobacterium longum BL19 (BL‐19) to treat the NAFLD mice induced by a high‐fat diet, and explored the treatment mechanism through gut microbiota and serum metabolomics techniques. We found that BL‐19 effectively prevented rapid weight gain in NAFLD mice and reduced their overall food and energy intake, decreased liver inflammatory factors expressions, and increased the bile acid synthetase enzyme CYP7A1 and superoxide dismutase. After BL‐19 treatment, the abundances of butyric acid bacteria (Oscillospira and Coprococcus) in the feces of mice increased significantly, and the concentration of butyric acid also increased significantly. We believe that BL‐19 promotes the production of butyrate in the intestines, which in turn regulates the activity of CYP7A1 in the liver and bile acid synthesis, ultimately treating liver inflammation and lipid accumulation in NAFLD mice. Serum metabolomics results indicated that BL‐19 affected multiple pathways related to inflammation and lipid metabolism in NAFLD mice. These findings suggest that BL‐19 shows promise as an adjunct therapy for NAFLD, as it can significantly improve oxidative stress, reduce inflammation in the liver, and decrease lipid accumulation.